| CAR | Chimeric antigen receptor |
| ATT | Adoptive T-cell therapy |
| ALL | Acute lymphoblastic leukemia |
| DLBCL | Diffuse large B-cell lymphoma |
| CSPG4 | Chondroitin sulfate proteoglycan 4 |
| scFv | Single-chain Fragment variable |
| FDA | Food and drug administration |
| EMA | European medicines agency |
| TME | Tumor microenvironment |
| MCSP | Melanoma-associated chondroitin sulfate proteoglycan |
| HMW-MAA | High molecular weight melanoma-associated antigen |
| NG2 | Neural/glial antigen 2 |
| GAG | Glycosaminoglycan |
| CS | Chondroitin sulfate |
| RTK | Receptor tyrosine kinases |
| PKCα | Protein kinase C alpha |
| MAPK | Mitogen-activated-protein-kinase |
| FAK | Focal adhesion kinase |
| TIL | Tumor-infiltrating lymphocyte |
| r/r | refractory and relapsing |
| FLT3 | FMS-like tyrosine kinase 3 |
| FLT3-ITD | FLT3 with internal tandem duplication |
| HSC | Hematopoietic stem cell |
| MLL | Mixed lineage leukemia |
| GBM | Glioblastoma |
| BiTE | Bi-specific T-cell engager |
| GSC | Glioblastoma stem cell |
| EGR1 | Early growth response protein 1 |
| TNBC | Triple-negative breast cancer |
| ER | estrogen receptors |
| EGFR | epidermal growth factor receptor |
| VEGFRvIII | Vascular endothelial growth factor receptor variant III |
| PARP | Poly(ADP-ribose) polymerase |